Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.
about
B cell regulation of the anti-tumor response and role in carcinogenesisGenetics and biology of pancreatic ductal adenocarcinomaPI3Kγ is a molecular switch that controls immune suppressionHif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia.The Basis of OncoimmunologyLack of immunoediting in murine pancreatic cancer reversed with neoantigen.Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma.SEOM Clinical Guideline for the treatment of pancreatic cancer (2016).Role of immune cells in pancreatic cancer from bench to clinical application: An updated reviewChemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors.Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival.Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis.What treatment in 2017 for inoperable pancreatic cancers?Pancreatic cancer stroma: controversies and current insights.Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.New insights in the development of pancreatic cancer.Innate immune mediators in cancer: between defense and resistance.Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.Tumour-associated macrophages as treatment targets in oncology.Targeting Immunotherapy to the Tumor Microenvironment.PI3K signaling in cancer: beyond AKT.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Cancer Manipulation of Host Physiology: Lessons from Pancreatic Cancer.Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.Distinct mechanisms of B and T lymphocyte accumulation generate tumor-draining lymph node hypertrophy.Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate.Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.Ibrutinib repurposing: from B-cell malignancies to solid tumors.Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma.Ibrutinib treatment improves T cell number and function in CLL patients.Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk.The Tumor Microenvironment at a Turning Point Knowledge Gained Over the Last Decade, and Challenges and Opportunities Ahead: A White Paper from the NCI TME Network.The PI3K Pathway in Human Disease.IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia.Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity.B cells as biomarkers: predicting immune checkpoint therapy adverse events.Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.Discovery of IDO1 Inhibitors: From Bench to Bedside.PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.
P2860
Q26738867-9936C308-20C8-4AE0-A086-6384AA653758Q26765438-08D9C7BA-EBE6-4639-A5B2-06C832BCD1ADQ33822173-D7898288-4064-4FDC-B1BF-CA5C3D009B13Q36664869-77FB71E9-4022-40E9-8D77-2E32D36550D5Q36678851-2DF92E4C-65DA-4C16-8A0D-3E379A344FD9Q37261700-5CF0A657-F82A-4D81-B5B8-B6DD2BB7BBCFQ37427668-1F96A576-3AC0-4450-AC6B-F295EFBE85FDQ37475173-9F0B7274-4DAF-4C46-99FD-B3CF989AD5B1Q37606102-01651A3B-6BBA-4C22-969E-B2A24A631410Q37660216-F2454FC4-6E9A-4AB9-9F8C-636944C89F4AQ37687298-A2613C19-89F0-461C-98FB-9759DF973832Q37741565-BE36E53F-8B69-45F5-9415-70B92AAD9BB0Q38375185-CFDAA53F-D3BB-41F0-9F17-4FF02A753031Q38689025-1CBCF508-DFA1-41B6-A73C-983E688DAF0FQ38748372-E943AF86-52AF-4A4B-973D-EF7F623CE82BQ38845812-57D2E900-45FD-4282-9AC4-4CDC6D80C1C8Q38907393-118464C4-F4EB-4BB1-BBA8-63E7391278AAQ38991015-44B29F74-52BE-48CF-AFC2-34F1A2BEDFFDQ39043404-1F7C1A4A-1302-4EEC-85F8-ADBE1FA2EFDDQ39100693-AB12488A-CAC7-49AA-8644-7F5BA9B952ACQ39195213-EBBB917E-25AD-4581-8288-E81100730E8FQ39200710-E140FCF5-EF49-4C17-A951-7B8746190C6CQ39204274-3D273FFB-339F-409B-B915-8726AEA72886Q39235761-F1F3EDF2-7C53-41FB-A03A-41923E69BBFBQ39766565-826FBF76-9562-4CC1-BE58-C2FDD8DCE3F5Q40994197-62C759BC-5E0A-4B1A-BDDE-DDFEC2841C42Q41064013-294A6013-42B1-4617-A0EB-7282097DF82CQ41701119-1AE87020-F81C-4E41-9DC3-B627FB042A55Q42267801-8DD32C78-659E-4704-ACD8-CF8AFF904C4FQ42776799-DC27578E-A211-4C55-A592-1D86C805CDD9Q42909982-66CD4042-9C2C-462B-A180-352541AC9EF9Q46011813-13D12E34-EABE-4E92-AB52-CCD66A29EEC6Q46026099-D7D12EE6-840D-4F9A-927F-18AC34BA2358Q46546002-9ECFCC45-DCAE-4EBF-A2C5-0C3D2E3C81A3Q47098673-E0475809-FE8A-4FD2-8C8C-9BDE88416B86Q47109965-57819B7D-5EBA-45A3-80AC-A1A61DDE0358Q47225274-9676B390-EAF1-4AD4-BFAF-392159CED106Q47388561-A2282AD5-E414-4D4D-BB33-3D4BBA551300Q47547812-7DD8567B-57F7-4A64-A3AC-F37B5AE02436Q48008350-BB1DF940-B14B-408D-AEEC-2C9A75009989
P2860
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.
@en
type
label
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.
@en
prefLabel
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.
@en
P2093
P2860
P50
P1433
P1476
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer
@en
P2093
Abraham V Nguyen
Andrew J Gunderson
Betty Y Chang
Bryan Irving
Douglas Hanahan
Lisa M Coussens
Margaret A Tempero
Megan M Kaneda
Morgan Truitt
P2860
P304
P356
10.1158/2159-8290.CD-15-0827
P577
2015-12-29T00:00:00Z